Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
$2.75
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.75
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.09 - $3.82
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.29M
Market Cap
$268.34M
Enterprise Value$210.67M
Total Cash (Recent Filing)$248.54M
Total Debt (Recent Filing)$59.98M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 13, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume4,363,874
30 Day Avg. Volume2,290,899
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.86
Enterprise Value/Gross Profit6.17
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$12.75Price Target Upside363.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Differentiated PlatformC4T's TORPEDO platform targets protein degradation rather than inhibition, a durable scientific differentiation. If the platform consistently yields selective degraders, it can create a long-term competitive advantage across oncology and inflammation, enabling multiple programs and higher exit potential per discovered target.
Strategic PartnershipsHigh-profile collaborations provide scientific validation, non-dilutive funding paths, and development/commercialization expertise. These partnerships can de-risk portions of clinical development, expand access to complementary assets, and materially strengthen execution capacity over multiple years.
Balance Sheet / RunwayManagement reports runway to end-2028 and balance sheet metrics show moderate leverage and sizable equity. This multi-year funding visibility supports planned Phase 1–3 sequencing and IND filings, reducing near-term financing pressure and allowing the company to pursue strategic clinical milestones.
Bears Say
Persistent Cash BurnOperating and free cash flow are deeply negative and have been consistently so, indicating structural cash burn from R&D and operations. Sustained negative cash generation forces reliance on external financing or partnerships, raising dilution risk and constraining optionality if trial timelines extend or costs rise.
Revenue Collapse & UnprofitabilityThe drop to zero reported revenue in 2025 and persistent operating losses mean the company lacks internal commercial cash flows to fund growth. This structural absence of revenue increases dependence on capital markets and partners and weakens the firm's ability to scale independently if clinical programs delay or fail.
Clinical & Execution RiskThe planned multi-year development program requires multiple successful trials and regulatory steps across indications and geographies. Biotech programs face high attrition; missing milestones or partner setbacks would materially impair the strategy, making execution risk a persistent structural constraint on eventual commercial success.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.08 and its highest was $3.82 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $268.34M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 59 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.108.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 97,578,180 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.361%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (363.64% Upside)
$12.75 (363.64% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.85%
12-Months-Change
Fundamentals
Return on Equity
-53.83%
Trailing 12-Months
Asset Growth
6.39%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$12.75
▲(363.64% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
1.64% Insiders
8.63% Mutual Funds
11.32% Other Institutional Investors
72.54% Public Companies and
Individual Investors